{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T07:11:22Z","timestamp":1713424282248},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T00:00:00Z","timestamp":1407801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00330-014-3378-4","type":"journal-article","created":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T13:48:50Z","timestamp":1407764930000},"page":"3191-3198","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Does tumoral 111In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing 90Y-ibritumomab radioimmunotherapy?"],"prefix":"10.1007","volume":"24","author":[{"given":"Koichiro","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,12]]},"reference":[{"key":"3378_CR1","first-page":"86","volume":"2","author":"PL Stevens","year":"2012","unstructured":"Stevens PL, Oluwole O, Reddy N (2012) Advances and application of radioimmunotherapy in non-Hodgkin lymphoma. Am J Blood Res 2:86\u201397","journal-title":"Am J Blood Res"},{"key":"3378_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/S0093-7754(03)00551-7","volume":"30","author":"RI Fisher","year":"2003","unstructured":"Fisher RI (2003) Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. Semin Oncol 30:3\u20139","journal-title":"Semin Oncol"},{"key":"3378_CR3","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","volume":"17","author":"TE Witzig","year":"1999","unstructured":"Witzig TE, White CA, Wiseman GA et al (1999) Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793\u20133803","journal-title":"J Clin Oncol"},{"key":"3378_CR4","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS et al (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336\u20134342","journal-title":"Blood"},{"key":"3378_CR5","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI et al (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262\u20133269","journal-title":"J Clin Oncol"},{"key":"3378_CR6","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453\u20132463","journal-title":"J Clin Oncol"},{"key":"3378_CR7","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","volume":"103","author":"LI Gordon","year":"2004","unstructured":"Gordon LI, Molina A, Witzig T et al (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study. Blood 103:4429\u20134431","journal-title":"Blood"},{"key":"3378_CR8","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdq024","volume":"21","author":"E Lopci","year":"2010","unstructured":"Lopci E, Santi I, Derenzini E et al (2010) FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Ann Oncol 21:1877\u20131883","journal-title":"Ann Oncol"},{"key":"3378_CR9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3816\/CLML.2010.n.054","volume":"10","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Gandolfi L, Stefoni V et al (2010) Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk 10:258\u2013261","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3378_CR10","author":"MM Andrade Campos","year":"2012","unstructured":"Andrade Campos MM, Montes Lim\u00f3n AE, Grasa JM, Lievano P, Baringo T, Giraldo P (2012) RIT with Y90-ibritumomab tiuxetan in follicular non-Hodgkin lymphoma: evaluation of recent outcomes in a single institution. J Oncol. doi: 10.1155\/2012\/412742","journal-title":"J Oncol"},{"key":"3378_CR11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s11604-012-0103-6","volume":"30","author":"M Nakagawa","year":"2012","unstructured":"Nakagawa M, Uike M, Choi I, Hayashi T, Uehara S (2012) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma. Jpn J Radiol 30:642\u2013647","journal-title":"Jpn J Radiol"},{"key":"3378_CR12","first-page":"99","volume":"45","author":"N Oriuchi","year":"2008","unstructured":"Oriuchi N, Koizumi K, Koizumi M et al (2008) Assessment for the image interpretation of 111In-ibritumomab tiuxetan in the phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Kaku Igaku 45:99\u2013113","journal-title":"Kaku Igaku"},{"key":"3378_CR13","first-page":"1812","volume":"46","author":"PS Conti","year":"2005","unstructured":"Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P (2005) The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med 46:1812\u20131818","journal-title":"J Nucl Med"},{"key":"3378_CR14","first-page":"12","volume":"11","author":"A Otte","year":"2008","unstructured":"Otte A (2008) Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma. Hell J Nucl Med 11:12\u201315","journal-title":"Hell J Nucl Med"},{"key":"3378_CR15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2967\/jnumed.108.052928","volume":"49","author":"A Iagaru","year":"2008","unstructured":"Iagaru A, Gambhir SS, Goris ML (2008) 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging. J Nucl Med 49:1809\u20131812","journal-title":"J Nucl Med"},{"key":"3378_CR16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijrobp.2005.01.017","volume":"63","author":"AS Gokhale","year":"2005","unstructured":"Gokhale AS, Mayadev J, Pohlman B, Macklis RM (2005) Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys 63:194\u2013201","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3378_CR17","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860\u20131861","journal-title":"Cancer Res"},{"key":"3378_CR18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. Clin Oncol 25:579\u2013586","journal-title":"Clin Oncol"},{"key":"3378_CR19","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","volume":"109","author":"TE Witzig","year":"2007","unstructured":"Witzig TE, Molina A, Gordon LI et al (2007) Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109:1804\u20131810","journal-title":"Cancer"},{"key":"3378_CR20","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773\u20131782","journal-title":"Eur J Cancer"},{"key":"3378_CR21","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00259-012-2079-y","volume":"39","author":"E Lopci","year":"2012","unstructured":"Lopci E, Zanoni L, Chiti A et al (2012) FDG PET\/CT predictive role in follicular lymphoma. Eur J Nucl Med Mol Imaging 39:864\u2013871","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-014-3378-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-014-3378-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-014-3378-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:33:58Z","timestamp":1565724838000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-014-3378-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3378"],"URL":"https:\/\/doi.org\/10.1007\/s00330-014-3378-4","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,12]]}}}